Inpharma 1380 - 29 Mar 2003

■ Filgrastim does not confer any added benefit inthe treatment of patients with infected diabetic footulcers, report researchers from Austria. Theyrandomised 37 patients with diabetes mellitus whohad a moderate-sized infected neuropathic foot ulcerof Wagner grade 2 or 3 to receive SC filgrastim (n =20) 5 µg/kg or placebo, once daily for up to 10 days incombination with in-hospital wound care and bed-rest.All of the patients received IV clindamycin andciprofloxacin until inflammation subsided. At studyend, cellulitis did not resolve any earlier amongfilgrastim, compared with placebo, recipients.Furthermore, improvements from baseline in theinfection summary score were not significantlydifferent between the two groups. However, ulcervolume was reduced from baseline by 59% amongfilgrastim recipients and by 35% among placeborecipients. The researchers suggest that factors otherthan filgrastim promoted the wound healing process.Kastenbauer T, et al. Evaluation of granulocyte-colony stimulating factor(filgrastim) in infected diabetic foot ulcers. Diabetologia 46: 27-30, Jan2003 800932794

1

Inpharma 29 Mar 2003 No. 13801173-8324/10/1380-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved